Lessons from immuno-oncology: a new era for cancer nanomedicine?

• Published in: Nature reviews. Drug discovery Vol. 16; no. 6; pp. 369 - 370
• Main Authors: Jiang, Wen, Yuan, Hengfeng, Chan, Charles K., von Roemeling, Christina A., Yan, Zuoqin, Weissman, Irving L., Kim, Betty Y. S.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-06-2017; Nature Publishing Group
• Subjects: 631/154/436; 631/67/1059/2325; 639/925/352/2733; 692/308/153; 692/700/565/251; Analysis; Animals; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cancer; Cancer Research; Care and treatment; comment; Drug Design; Humans; Immunotherapy - methods; Medicinal Chemistry; Molecular Medicine; Nanomedicine; Nanomedicine - methods; Neoplasms - immunology; Neoplasms - therapy; Pharmacology/Toxicology; Quality control; Technology application; Translational Medical Research - methods
• ISSN: 1474-1776; 1474-1784
• DOI: 10.1038/nrd.2017.34

Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.
Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.